Morgan Stanley raises Regeneron Pharmaceuticals (NASDAQ:REGN) price target from $897 to $912

By legume / August 5, 2023 / Morgan Stanley, Regeneron Pharmaceuticals

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $897 to $912.